Archive for the ‘Autism’ Category

Medical Police State Cuts Off Research Funding From Scientist Who Found That Vaccines Cause Autism

https://www.naturalnews.com/2019-04-11-medical-police-state-cuts-off-research-funding-from-scientist-vaccines.html

Medical police state cuts off research funding from scientist who found that vaccines cause autism

Image: Medical police state cuts off research funding from scientist who found that vaccines cause autism

(Natural News) When it comes to the Religion of Vaccination, there’s one area of research that’s completely off-limits, and it encompasses looking into vaccine safety and effectiveness independently, and with an open mind. The reason for this, of course, is that every time a scientist dares to do this, he or she typically discovers that vaccines aren’t nearly as safe or effective as the medical police state claims – which instantly makes said scientist a target of the medical establishment, which has no qualms about doing almost anything in order to silence the truth.

One recent and prominent example of this type of medical tyranny involves Professor Chris Exley of Keele University in the United Kingdom, whose focused research into aluminum toxicity led him to conclude that childhood vaccines, many of which contain neurotoxic aluminum, can, in fact, cause autism – a discovery that, if you’ve been following independent vaccine science for any considerable period of time, is inherently “controversial” and a recipe for trouble.

Like Dr. Andrew Wakefield before him, Prof. Exley merely reported his findings in the interest of public health, as any good scientist would do. And in the process, he’s made himself enemy number one of the Vaccine Mafia, which is now trying to destroy his career and life by barring him from raising any further funding for his research endeavors.

In essence, Prof. Exley has officially blown the lid off the highly-destructive nature of aluminum in vaccines, indicating that this common chemical adjuvant has the potential to cause “severe and disabling” autism in children who are injected with it. And for violating the medical establishment’s never-to-be-challenged doctrine of “all vaccines are safe and effective,” Prof. Exley is now having to endure the ire of the priests and priestesses of the Cult of Vaccination, which are now out for blood.

Support Prof. Exley’s GoFundMe to help bring the truth about vaccines and autism to as many people as possible

Prof. Exley was one of the underwriters for an eye-opening 2017 study published in EBioMedicine, a journal associated with The Lancet, which found that underarm cosmetic products – mainly antiperspirant deodorants that contain aluminum – increase users’ risk of developing breast cancer.

He’s also studied other areas of aluminum toxicity similarly unrelated to vaccines – though vaccines eventually became a natural next-step for his particular area of focus. And rather than censor the progressive course of his research endeavors, Prof. Exley stuck true to science – and for doing this, he’s now paying a big price.

The good news, though, is that many people are on Prof. Exley’s side, and are working hard to get him funding from other sources. Some of his most ardently faithful followers have actually set up a GoFundMe page to help raise financial support for his continued research endeavors.

In light of the medical establishment’s continued betrayal of not only his work but also science at large, it’s up to everyday folks who care about truth to step up to the plate to make sure that parents know the truth – and more importantly, to ensure that as many children as possible are protected against toxic injections that could cause them lifelong harm.

“We’ve seen this drama unfold many times,” comments Age of Autism about this latest saga.

“A well respected doctor or researcher begins to ask questions about vaccine safety as a result of the science he or she conducts, and his career is adversely affected[Prof. Exley’s] funding is dwindling and he needs our help.”

Also, be sure to check out the book How to End the Autism Epidemic by J.B. Handley.

Sources for this article include:

TheTimes.co.uk

ScienceDirect.com

AgeOfAutism.com

JBHandleyBlog.com

__________________

**Comment**

The following graph pretty much says it all:

Neil+Miller

The following information taken from the Organic Lifestyle magazine shows the censorship happening on anyone who departs from the accepted narrative that touts vaccines are safe:  https://www.organiclifestylemagazine.com/doctor-asks-fda-to-reconsider-safe-levels-of-aluminum-gets-censored-and-suspended-on-medium 

Dr. James Lyons-Weiler’s published a study, Reconsideration of the immunotherapeutic pediatric safe dose levels of aluminum, that says the recognized safe aluminum levels in vaccines are based on immune efficacy and ignore body weight. James says that several critical mistakes have been made in the consideration of pediatric dosing of aluminum and that safety inferences of vaccine doses of aluminum have relied solely on dietary (ingested, not injected) exposure studies of adult mice and rats.

On Day 1 of life, infants receive 17 times more aluminum than would be allowed if doses were adjusted per body weight.

The FDA states that 850 mcg of aluminum is safe for an adult. With his research, James found that a series of errors led to the guidelines that state 850 mcg of aluminum is safe for an adult.

The first serious problem (Problem #1) is that a provisionally tolerable weekly limit assumed to be safe was, by a series of errors and bad assumptions, transformed into a daily limit that appeared to be backed by studies. The studies used were not up to date, and the FDA’s determination used spurious estimates to transform safety information from dietary studies of adult mice into injected safe limits in human infants. These errors were made, in part, in the pediatric limit consideration by the FDA, who used outdated information not consistent with other organizations like World Health Organization.

To add to the confusion, the 1 mg/kg/week was also then changed to 2 mg/kg/week. The ATDSR used information from one study, assumed 1 mg/kg/week, adjusted using arbitrary functions that are without a doubt as good as a bad guess.

The provenance of these errors is reviewed further below, and in our newly published study.”

We came across this study last week on Medium. It has since been deleted, along with Jame’s account. We checked on web.archive.org to see if the page had been preserved; it had not. We searched Google, but it’s gone from search results, but we did find the article republished by James on LinkedIn.

This Open Letter originally appeared on Medium.com. Due to their censorship, it is ported here.= JLW. It is based on peer-reviewed studies.” – Dear FDA: Please Reconsider “Safe” Levels of Aluminum…

We also noticed that Jame’s Medium account has been suspended. And Bing is a little slower to eliminate the search results. If you want, click here to see their Cached version while it’s still available, but you can also read the full article republished on LinkedIn.

Related: Doctors Against Vaccines – Hear From Those Who Have Done the Research

Articles on aluminum in vaccines:  https://vactruth.com/?s=safe+levels+of+aluminum

For a great site on all things vaccine related.  There is a list of scientific articles: https://vaccinepapers.org

 

 

 

Autism Symptoms Reduced Nearly 50% Two Years After Fecal Transplant

https://scienceblog.com/507184/autism-symptoms-reduced-nearly-50-two-years-after-fecal-transplant/

Autism Symptoms Reduced Nearly 50% Two Years After Fecal Transplant

Recent research suggests our gut microbiomes affect brain communication and neurological health. Worldwide, interest is growing in the idea that changes in normal gut microbiota may be responsible for triggering various conditions. At ASU, a research team is exploring using the microbiome to treat autism symptoms.

According to the Centers for Disease Control and Prevention, about one in every 59 children in the U.S. is diagnosed with autism, up from one in every 150 in 2000. They report that

“about half a million people on the autism spectrum will become adults over the next decade, a swelling tide for which the country is unprepared.”

The apparent rise in autism spectrum disorder (ASD) and its stubborn resistance to treatment has spurred a legion of researchers to enter the field and explore the disability in innovative ways.

Currently, effective treatments for ASD include behavioral therapy, speech and social therapy, psychiatric medications, and dietary and nutritional approaches. However, no medical treatments have been approved to treat core symptoms of ASD such as social communication difficulties and repetitive behaviors.

One promising avenue of autism research involves the gut microbiome, which is the collection of microbes that lives in our intestines and helps us in many ways including digestion of our food, training our immune system and preventing overgrowth of harmful bacteria. Recent research suggests our gut microbiomes also affect brain communication and neurological health. Worldwide, interest is growing in the idea that changes in normal gut microbiota may be responsible for triggering a vast range of diseases.

In a new study, “Long-term benefit of Microbiota Transfer Therapy in Autism Symptoms and Gut Microbiota,” published in Scientific Reports, Arizona State University researchers Rosa Krajmalnik-Brown, Ph.D., James Adams, Ph.D, and lead author Dae-Wook Kang, Ph.D, demonstrate long-term beneficial effects for children diagnosed with ASD through a revolutionary technique known as Microbiota Transfer Therapy (MTT), a special type of fecal transplant originally pioneered by Dr. Thomas Borody, an Australian gastroenterologist.

Remarkably, improvements in gut health and autism symptoms appear to persist long after treatment.

At two years post-treatment, most of the initial improvements in gut symptoms remained. In addition, parents reported a slow steady reduction of ASD symptoms during treatment and over the next two years. A professional evaluator found a 45% reduction in core ASD symptoms (language, social interaction and behavior) at two years post-treatment compared to before treatment began.

“We are finding a very strong connection between the microbes that live in our intestines and signals that travel to the brain,” said Krajmalnik-Brown, a professor at the Biodesign Swette Center for Environmental Biotechnology at the Biodesign Institute and ASU’s School for Sustainable Engineering and the Built Environment. “Two years later, the children are doing even better, which is amazing.”

Many kids with autism have gastrointestinal problems, and some studies, including ours, have found that those children also have worse autism-related symptoms,” said Krajmalnik-Brown. “In many cases, when you are able to treat those gastrointestinal problems, their behavior improves.

Roughly 30-50% of all people with autism have chronic gastrointestinal (GI) problems, primarily constipation and/or diarrhea that can last for many years. That chronic discomfort and pain can cause irritability, decreased attention and learning, and negatively impact behavior.

An earlier study with only vancomycin (an antibiotic) had found major temporary improvements in GI and autism symptoms, but the benefits were lost a few weeks after treatment stopped despite use of over-the-counter probiotics.

So, the question at hand was what’s going on in the gut, and how does it affect both physical and behavioral symptoms of autism, and how can we develop a long-lasting treatment?

Krajmalnik-Brown, Kang and Adams have shown that by transferring healthy microbiota to individuals lacking certain gut bacteria, it is possible to “donate” a more diverse set of bacteria into the patient and improve gut health.

In Australia, Fecal Microbiota Transplantation (FMT) was initially developed by Borody. At his Centre for Digestive Diseases in Sydney, Borody has overseen more than 18,000 FMTs for various disorders since 1987. He pioneered in Australia the use of FMT for colitis and Clostridium difficile infection, and was the first to use oral FMT to treat children with ASD. Only one dose of FMT is usually enough to cure C. Difficile infections, but his patients with autism were far harder to treat. He discovered that three months of daily FMT was required to treat his autism patients, but eventually resulted in significant improvements in both GI and autism symptoms.

Based on his experience with his patients, Borody led the design of the clinical treatment used at ASU for this study. The MTT approach involves 10 weeks of treatment, including pre-treatment with vancomycin, a bowel cleanse, a stomach acid suppressant, and fecal microbiota transfer daily for seven to eight weeks.

The initial open-label study, led by Krajmalnik-Brown and Adams, and published in the journal Microbiome in 2017, concluded that “this exploratory, extended-duration treatment protocol thus appears to be a promising approach to alter the gut microbiome and improve GI and behavioral symptoms of ASD. Improvements in GI symptoms, ASD symptoms, and the microbiome all persisted for at least eight weeks after treatment ended, suggesting a long-term impact.” The present study now shows the benefits are extended beyond eight weeks to at least two years post-treatment.

The ASU team compared differences in the microbiome of children with autism compared to typically developing children. At the start of the study, children with autism were found to have lower diversity in their respective gut microbes and were depleted of certain strains of helpful bacteria, such as Bifidobacteria and Prevotella.

“Kids with autism are lacking important beneficial bacteria, and have fewer options in the bacterial menu of important functions that bacteria provide to the gut than typically developing kids,” Krajmalnik-Brown said.

FMT treatment substantially increased microbial diversity and the presence of helpful bacteria in the gut, such as Bifidobacteria and Prevotella. After two years, diversity was even higher and the presence of beneficial microbes remained.

“We originally hypothesized that our therapy would be efficient to transform the dysbiotic gut microbiome toward a healthy one. In our original paper in 2017, we reported an increase in gut diversity together with beneficial bacteria after MTT, and after two years, we observed diversity was even higher and the presence of beneficial microbes remained,” Kang said.

He added that this may be one of the reasons for success in improving the gut health, but further mechanistic studies are warranted to define specific roles of gut microbes in the context of autism.

The work done at ASU is not only about treating patients but also about learning from the treatment in order to develop better formulations and optimize dosing.

“Understanding which microbes and chemicals produced by the microbes are driving these behavioral changes is at the heart of our work,” Krajmalnik-Brown said. The team’s new publication reports that the study demonstrated that two years after treatment stopped the participants still had an average of a 58% reduction in GI symptoms compared to baseline. In addition, the parents of most participants reported “a slow but steady improvement in core ASD symptoms.”

“Every family completed the study, and every family returned two years later for a follow-up evaluation,” said Adams, citing the families’ dedication to the research. “The treatment was generally well-tolerated with minimal adverse effects.”

“This is a world-first discovery that when we treated the gut bacteria in these children during our clinical trial two years ago to reset their microbiome with FMT, positive results are still continuing to be improving two years from the original treatments. I would call it the highest improvement in a cohort that anyone has achieved for autism symptoms,” said Borody.

Professional evaluation revealed a 45% decrease in ASD symptoms compared to baseline. Researchers note that although there may be some placebo effect, much of that effect appears to be real. At the start of the study, 83% of participants were rated as “severe” autism. At the end of the study, only 17% were “severe,” 39% were “mild/moderate,” and 44% were below the cut-off for mild ASD.

Greg Caporaso, at Northern Arizona University, a leading expert in microbiome data science and a co-author on these studies, helped to analyze the microbiome data to better understand bacterial changes as a result of MTT.

“Drs. Krajmalnik-Brown, Kang and I are excited about the results, but we want to caution the public that we need larger clinical trials for this to become an FDA-approved treatment,” said Adams. Professional expertise is required for safe and effective treatment.

MTT improves GI distress by introducing key strains of beneficial bacteria and helping to raise levels of biodiversity within the gut, boosting health overall.

Adams has both professional and personal reasons for doggedly pursuing ways to help children with autism because he knows the situation first-hand. His daughter was diagnosed with autism just before her third birthday. Adams, a President’s Professor at ASU’s School for Engineering of Matter, Transport and Energy, and the chair of Materials Sciences, is also president of the Autism Society of Greater Phoenix, the largest parent support group in Arizona.

“Dr. James Adams is the reason why I started working on autism,” Krajmalnik-Brown said. “I had the methods to do all of the measurements and assessments in the microbiome part of the work, and he had the autism knowledge.”

Adams recruited patients, supervised clinical work and ASD assessments, and guided the patients through the trials, and Krajmalnik-Brown led the microbiome evaluations and helped plan the study.

All of the participants in the study exhibited chronic GI symptoms from infancy, including chronic constipation and/or chronic diarrhea. The treatment benefits extended beyond their physical symptoms, even causing some parents to note how much their children’s behavior had improved over time.

“It is very unusual to see steady gradual improvement after the conclusion of any treatment,” said Adams. “We only conducted the long-term follow-up study after several families told us that their child was continuing to improve significantly.”

Krajmalnik-Brown stated that the data suggests that the MTT intervention transformed the gut environment into a healthier status, leading to long-term benefit on both GI and ASD symptoms.

Adams said many of the participants in the trial shared common traits, including

  • birth by C-section
  • reduced breastfeeding
  • increased antibiotics
  • low fiber intake by the mother and child

All of these lead to limited biodiversity in their gut bacteria. Due to the open label nature of the study and the small sample size used, more research is needed in order to verify the usefulness of MTT as a therapeutic.

The initial study involved a “first-generation” estimate as to optimal dose and duration of treatment, and it was enough for 90% of the children to have substantial benefit. The team is now working on optimizing the dosing and duration to try to improve benefits even more, and to determine if booster doses may be needed in some cases.

__________________

For more:  https://madisonarealymesupportgroup.com/2017/12/11/bitter-pill-to-swallow-for-c-diff/

https://madisonarealymesupportgroup.com/2019/02/19/germs-in-your-gut-are-talking-to-your-brain-scientists-want-to-know-what-theyre-saying/

https://madisonarealymesupportgroup.com/2019/01/12/sibo-clinical-implications-natural-therapeutic-options/

https://madisonarealymesupportgroup.com/2019/03/29/cochrane-review-probiotics-reduce-c-diff-by-70-in-high-risk-patients-taking-antibiotics/

https://madisonarealymesupportgroup.com/2018/09/15/prebiotics-probiotics-do-they-really-work-for-gut-health/

https://madisonarealymesupportgroup.com/2019/01/18/investigational-c-diff-treatment-granted-fast-track-designation/

AutismOne 2019 Chicago Conference in May – Dr. Brown Speaking

conf-2019

Register here:  https://autismone.ticketspice.com/autism-one-2019-conference

The most rewarding educational and networking experience you can have at any autism conference!  An exceptional value as you gather new hope, answers, help, and direction.

New to the autism diagnosis? Come hear the “Newly Diagnosed” track just for you!
Yearning to learn more? Hear the “Biomedical Research and Treatments” track!

This conference will help you answer and understand important concepts:

  • Recovery from autism is possible and children get better!
  • There are medical comorbidities of autism that, when treated, allow the child to enjoy improved learning and behavior.

On the autism journey a little while? Come hear the latest research and healing information!
Medical professional? Hear renowned researchers present the latest cutting-edge autism research.

Conference track highlights include:
  • Membrane Medicine track
  • PANDAS/PANS track (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome)
  • 4th Annual International HPV Vaccine Education Symposium
  • Focus for Health Advocacy Training track
  • Chiropractic Pediatric Continuing Education Credit Program with Emphasis on Autism
  • Endocannabinoid Medicine track
  • ADHD (attention-deficit/hyperactivity disorder) track
  • Culinary Day: Culinary Day on a Budget
  • And a special surprise panel that illuminates the bigger picture that affects your family’s world

The AutismOne 2019 Conference will be held May 22-26, 2019, at the Loews Chicago O’Hare Hotel in Rosemont, IL.

“AutismOne always has the cutting-edge information years ahead of any other autism conference. You hear it first at AutismOne.” ~Janet Cakir, PhD

CONFERENCE SCHEDULE-AT-A-GLANCE

WEDNESDAY, MAY 22, LECTURES:
1:30PM-6:00PM

THURSDAY, MAY 23, LECTURES, MOVIES, PANELS:
8:30AM-10:15PM

FRIDAY, MAY 24, LECTURES AND PANELS:
8:30AM-5:45PM

SATURDAY, MAY 25, LECTURES AND PANELS:
8:30AM-7:00PM

SUNDAY, MAY 26, LECTURES:
8:45AM-1:30PM

See list of speakers:  https://autismoneconference.com/conference_speakers.html  Erica Linn, MSN & Dr. Greg Brown MD from Serenity Health in Wisconsin will be speakers at the conference.  Dr. Brown treats children and adults with Lyme/MSIDS as well as PANS/PANDAS.  He’s stated that up to 80% of his autistic and PANS/PANDAS patients are infected with Lyme/MSIDS.

For more on that connection:  https://madisonarealymesupportgroup.com/2017/10/01/panspandas-steroids-autoimmune-disease-lymemsids-the-need-for-medical-collaboration/

https://madisonarealymesupportgroup.com/2017/10/08/misdiagnosed-how-children-with-treatable-medical-issues-are-mistakenly-labeled-as-mentally-ill/

https://madisonarealymesupportgroup.com/2017/06/30/child-with-lymemsidspans-told-by-doctors-she-made-it-all-up/

https://madisonarealymesupportgroup.com/2017/10/09/today-is-panspandas-awareness-day/  Trifiletti officially diagnosed Carson with PANS, not PANDAS, due to the active co-infections found in his blood work: mycoplasma, the bacteria that causes pneumonia; coxsackie — the virus causing Hand, Foot and Mouth disease; streptococcus, the bacteria causing strep throat; bartonella and babesia — a bacteria and parasite related to Lyme disease; and yeast, Melissa Spears said.

Instead of attacking these infections, Carson’s antibodies were instead going after his brain.

https://madisonarealymesupportgroup.com/2018/03/14/dr-frid-children-lyme/

Autism & Parenting: Helpful Caregiving Tips Podcast

http://brainwarriorswaypodcast.com/autism-parenting-helpful-caregiving-tips/

Click on link for podcast.

DR. DANIEL G. AMEN, MD on The Brain Warrior's Way Podcast

DANIEL G. AMEN, MD

Dr. Amen is a NY Times best-selling author, double board-certified psychiatrist and brain-imaging pioneer. He is watched by millions of viewers on his breakthrough public television programs about brain health. His research was listed as one of the top 100 stories in science in 2015 by Discover Magazine.

TANA AMEN, BSN RN on The Brain Warrior's Way Podcast

TANA AMEN, BSN, RN

Tana is VP of Amen Clinics, a highly-respected health and fitness expert, nurse and author of six books, including the NY Times bestseller The Omni Diet. Tana’s fresh approach and energetic presence have made her a nationally renowned speaker. As an in-demand media guest, she has appeared on TV shows including, The Doctors, The Today Show and Good Day New York.

 

The experience of parenting a child with a disability such as autism or cerebral palsy is vastly different than the usual parenting experience. There’s often grief, guilt, and shame, and even feelings of underperforming or letting your child down. In the second episode of a series on caregiving, Dr. Daniel Amen and Tana Amen give you tips to change your way of thinking to enable you to help guide and care for your child in a more productive way.

 

Prevalence of Autism Study Comparing Vaccination Schedules in a Pediatric Patient Population

 Approx. 2 Min

New comparative Autism Rate Data Study

Published March 14, 2019

Dr. Paul Thomas commissioned an independent quality assurance project.  The researcher found 3,345 patients born into Thomas’ practice in the last 10.5 years.

  • 715 in his practice had ZERO vaccines. Autism rate 1 in 715.
  • Remaining 2,630 followed his “vaccine friendly” schedule getting between 7-18 vaccines. There were 6 cases making the Autism rate 1 in 440.
  • The recommended CDC schedule mandates kids of this age group get 25-40 vaccines with an Autism rate of 1 in 45.
The “vaccine friendly” plan gave 1,000% improvement from the CDC vaccine schedule.

Speaking of “real life” data, in the first ever patient sample in Lyme, Connecticut, only a quarter of the patients had the EM rash, yet the CDC tells us it’s between 70-80%: https://madisonarealymesupportgroup.com/2019/02/22/why-mainstream-lyme-msids-research-remains-in-the-dark-ages/

Hmmmmm…..